Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIKAMIC: Hydroxycarbamide for Albuminuria in Sickle Cell Disease
NCT03806452Phase 2Completed
- Sponsor
- Theravia
- Start
- May 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing Hydroxycarbamide with Placebo (2 arms). Primary endpoint: Number of Patients Achieving at Least a 30% Decrease in ACR Baseline Value at 6 months. Started May 2019; status: completed.
02
Drugs
hydroxyurea
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03806452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03806452.